Andre Goy, MD, John Theurer Cancer Center

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

September 20th 2021

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL

May 6th 2021

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Goy on the Potential Utility of Liso-Cel in MCL

April 19th 2021

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on Updates in Precision Medicine in Oncology

September 26th 2020

Andre Goy, MD, MS, discusses updates in precision medicine. 

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

July 17th 2020

SADAL Trial Regimen FDA Approval

July 17th 2020

SADAL Trial Overview

July 17th 2020

CAR T-Cell Therapy Clinical Trials

July 17th 2020

CAR T-Cell Therapy Response Rates

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

July 17th 2020